Central Nervous System Tumor

Interventional

Drug Intervention

IRB# STUDY00021117
PNOC 017: A Target Validation/Phase 1 Study of BGB-290 in Combination with Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas.

IRB# STUDY00021284
(Advrra-IRB) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation.

IRB# STUDY00022263
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety, and Tolerability of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php